Biological
Blood samples for PK
Blood samples for PK is a biological therapy with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph phase_1
1
25%
Ph phase_4
1
25%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting2
Not yet recruiting2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 11 (50.0%)
Phase 41 (50.0%)
Trials by Status
recruiting250%
not_yet_recruiting250%
Recent Activity
2 active trials
Showing 4 of 4
not_yet_recruiting
Individualized Dose of Fibrinogen Following Cardiopulmonary Bypass
NCT07425600
not_yet_recruitingphase_4
Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer
NCT07490509
recruitingphase_1
Study With [225Ac]Ac-FL-020 in mCRPC Participants
NCT06492122
recruiting
Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
NCT06663111
Clinical Trials (4)
Showing 4 of 4 trials
NCT07425600
Individualized Dose of Fibrinogen Following Cardiopulmonary Bypass
NCT07490509Phase 4
Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer
NCT06492122Phase 1
Study With [225Ac]Ac-FL-020 in mCRPC Participants
NCT06663111
Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4